Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer

@article{Stamey1993LocalizedPC,
  title={Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer},
  author={Thomas Alexander Stamey and Fuad S. Freiha and John E. McNeal and Elise A. Redwine and Alice S. Whittemore and Hans-Peter Schmid},
  journal={Cancer},
  year={1993},
  volume={71}
}
Background. Using the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute and American total mortality rates, the authors calculated the probability at birth of having a diagnosis of prostate cancer within a man's life to be 8.8% and then subtracted the incidence of microscopic Stage A cancers too small to ever be clinically significant. This gave a final probability of 8%. 
The clinical significance of a small focus of well‐differentiated carcinoma at prostate biopsy
To compare a series of 121 sextant needle biopsy sets with their corresponding radical prostatectomy specimens in screened participants in the European Randomized study of Screening for ProstateExpand
Prediction of significant cancer in men with stage Tic adenocarcinoma of the prostate
TLDR
Pre-treatment criteria that include PSA density and prostate biopsy findings provide the means to assess the significance of prostate cancer after diagnosis. Expand
Relationship between serum prostate specific antigen, needle biopsy findings, and histopathologic features of prostatic carcinoma in radical prostatectomy tissues
TLDR
The pretreatment prediction of those carcinomas of the prostate that are likely to be clinically aggressive is an important objective and this work aims to improve that prediction. Expand
The results of prostate carcinoma screening in the U. S. As reflected in the surveillance, epidemiology, and end results program
TLDR
The rapid escalation in the incidence of prostate carcinoma between the years 1988 and 1992 has been attributed to prostate specific antigen screening andcriptive studies suggest that serial screening decreases the detection of advanced disease. Expand
Pathologic findings and prostate specific antigen outcome after radical prostatectomy for patients diagnosed on the basis of a single microscopic focus of prostate carcinoma with a Gleason score ≤ 7
Whether patients who are diagnosed on the basis of a single microscopic focus of prostate carcinoma with a Gleason score ≤ 7 (micro PC) have potentially life‐threatening disease if they are notExpand
Observations on the doubling time of prostate cancer. The use of serial prostate‐specific antigen in patients with untreated disease as a measure of increasing cancer volume
TLDR
This work has shown that changes in PSA in untreated patients should reflect tumor growth rate and the shape of the growth curve, and aims to clarify the role of serum marker prostate‐specific antigen in prostate cancer diagnosis. Expand
Prediction of potentially insignificant prostate cancer in men undergoing radical prostatectomy for clinically organ‐confined disease
Abstract  Background:  The objectives of the present study were to characterize, according to tumor significance, the clinicopathological features of patients with prostate cancer who underwentExpand
Focal Therapies for Localized Prostate Cancer
TLDR
Focal therapy potentially offers cancer control, without the side effect profile of radical therapies, and ablation is targeted at the cancer itself with preservation of surrounding normal tissue. Expand
Evaluation of a Nomogram used to predict the pathologic stage of clinically localized prostate carcinoma
TLDR
A Nomogram based on pretreatment prostate specific antigen (PSA) level, tumor grade, and clinical stage, developed and distributed to physicians to aid physicians in making treatment recommendations by predicting the probability of the final pathologic stage of clinically localized prostate carcinoma. Expand
Primary staging of prostate cancer
TLDR
An overview of different staging modalities is given and the need for incorporation of prognostic factors, such as tumour grade and volume, in the staging system is emphasized. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 26 REFERENCES
Observations on the doubling time of prostate cancer. The use of serial prostate‐specific antigen in patients with untreated disease as a measure of increasing cancer volume
TLDR
This work has shown that changes in PSA in untreated patients should reflect tumor growth rate and the shape of the growth curve, and aims to clarify the role of serum marker prostate‐specific antigen in prostate cancer diagnosis. Expand
Incidental carcinoma of the prostate: an analysis of the predictors of progression.
TLDR
A retrospective study of 232 patients with incidentally discovered prostate cancer demonstrated a significant advantage of survival free of disease for patients presenting with tumors manifesting a lower Gleason score and volume extent. Expand
The predictive significance of substaging stage A prostate cancer (A1 versus A2) for volume and grade of total cancer in the prostate.
TLDR
Post-resection serum prostate specific antigen (PSA) levels were elevated with increasing total residual cancer volume in the radical specimen, and unsuspected cancers unrelated to the tumor detected at transurethral resection were found in theradical prostatectomy specimen. Expand
PATTERNS OF PROGRESSION IN PROSTATE CANCER
TLDR
It was concluded that the natural history of prostate cancer is highly predictable and the capacity to metastasise probably develops only in tumours which have grown much larger than 1 ml and acquired poorly differentiated areas as a manifestation of the phenomenon of tumour progression. Expand
Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate
The Gleason grading system for prostate cancer was applied quantitatively to analysis of entire tumors in 209 radical prostatectomy specimens from patients with clinical Stage A and Stage BExpand
Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors
TLDR
It was concluded that additional incidental tumors are common in patients with prostate cancer, but their sum of volumes is seldom as large as the clinical cancer volume. Expand
NATURAL HISTORY OF LOCALISED PROSTATIC CANCER A Population-based Study in 223 Untreated Patients
TLDR
It is concluded that tumour grade at diagnosis is an excellent predictor of local and distant progression and the low death rate, especially in patients with highly and moderately differentiated tumours means that any local or systemic therapy intended for patients with early prostatic cancer must be evaluated in clinical trials with untreated controls for comparison. Expand
Family history and the risk of prostate cancer
A case‐control study was performed to estimate the relative risk of developing prostate cancer for men with a positive family history. Extensive cancer pedigrees were obtained on 691 men withExpand
Origin and development of carcinoma in the prostate
TLDR
Detailed histologic study of 45 cancerous prostate glands in 134 autopsies provided new information on the natural history of prostatic carcinoma, suggesting a gradual increase in biologic malignant potential which is closely linked to tumor size. Expand
The distribution of residual cancer in radical prostatectomy specimens in stage A prostate cancer.
TLDR
The greatest threat to patients with stage A prostate cancer may be a separate, associated cancer in the peripheral zone rather than the primary transition zone cancer incidentally removed at transurethral resection. Expand
...
1
2
3
...